2023 Q2 Form 10-Q Financial Statement

#000165495423005861 Filed on May 05, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $315.0K $476.0K
YoY Change 13.72% 23.0%
% of Gross Profit
Research & Development $555.0K $275.0K
YoY Change -41.64% 21.68%
% of Gross Profit
Depreciation & Amortization $6.000K $6.000K
YoY Change -25.0% -25.0%
% of Gross Profit
Operating Expenses $876.0K $757.0K
YoY Change -29.13% 21.9%
Operating Profit
YoY Change
Interest Expense -$164.0K $377.0K
YoY Change -59.8% 138.61%
% of Operating Profit
Other Income/Expense, Net -$164.0K $377.0K
YoY Change -63.96% 252.34%
Pretax Income -$1.040M -$380.0K
YoY Change -38.5% -26.07%
Income Tax
% Of Pretax Income
Net Earnings -$1.040M -$380.0K
YoY Change -38.5% -26.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.02 -$0.01
COMMON SHARES
Basic Shares Outstanding 64.80M shares 64.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.624M $4.881M
YoY Change 944.56% 177.65%
Cash & Equivalents $496.0K $440.0K
Short-Term Investments $3.128M $4.441M
Other Short-Term Assets $366.0K $26.00K
YoY Change 351.85% -91.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.990M $4.907M
YoY Change -44.87% -43.53%
LONG-TERM ASSETS
Property, Plant & Equipment $16.84M $16.76M
YoY Change 2.21% 1.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.000K $4.000K
YoY Change -97.58% -33.33%
Total Long-Term Assets $16.85M $16.76M
YoY Change 2.21% 1.9%
TOTAL ASSETS
Total Short-Term Assets $3.990M $4.907M
Total Long-Term Assets $16.85M $16.76M
Total Assets $20.84M $21.67M
YoY Change -12.16% -13.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $235.0K $188.0K
YoY Change -52.04% -18.26%
Accrued Expenses $31.00K $25.00K
YoY Change -26.19% -32.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $274.0K $213.0K
YoY Change -48.5% -20.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $195.0K $125.0K
YoY Change 40.29% -16.67%
Total Long-Term Liabilities $195.0K $125.0K
YoY Change 40.29% -16.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $274.0K $213.0K
Total Long-Term Liabilities $195.0K $125.0K
Total Liabilities $469.0K $338.0K
YoY Change -30.1% -18.94%
SHAREHOLDERS EQUITY
Retained Earnings -$55.31M -$54.27M
YoY Change 6.03%
Common Stock $649.0K $648.0K
YoY Change 0.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.37M $21.33M
YoY Change
Total Liabilities & Shareholders Equity $20.84M $21.67M
YoY Change -12.16% -13.8%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$1.040M -$380.0K
YoY Change -38.5% -26.07%
Depreciation, Depletion And Amortization $6.000K $6.000K
YoY Change -25.0% -25.0%
Cash From Operating Activities -$1.080M -$685.0K
YoY Change 60.0% 14.74%
INVESTING ACTIVITIES
Capital Expenditures $9.000K $0.00
YoY Change -118.37% -100.0%
Acquisitions
YoY Change
Other Investing Activities $1.131M $809.0K
YoY Change 56.22% -152.13%
Cash From Investing Activities $1.122M $809.0K
YoY Change 66.22% -151.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.00K 0.000
YoY Change 1300.0% -100.0%
NET CHANGE
Cash From Operating Activities -1.080M -$685.0K
Cash From Investing Activities 1.122M $809.0K
Cash From Financing Activities 14.00K 0.000
Net Change In Cash 56.00K $124.0K
YoY Change 5500.0% -205.98%
FREE CASH FLOW
Cash From Operating Activities -$1.080M -$685.0K
Capital Expenditures $9.000K $0.00
Free Cash Flow -$1.089M -$685.0K
YoY Change 73.96% 16.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
757000 usd
CY2023Q1 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
27000 usd
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-51000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
213000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-514000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
380000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
514000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
329000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
213000 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
67000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
125000 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64801373 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
648000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
74953000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54268000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21333000 usd
CY2022Q4 us-gaap Assets
Assets
22034000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
228000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
213000 usd
CY2023Q1 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
125000 usd
CY2022Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
125000 usd
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
125000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64801373 shares
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
316000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
3951000 usd
CY2023Q1 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
1278000 usd
CY2022Q4 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
949000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
5254000 usd
CY2022Q4 us-gaap Mineral Properties Net
MineralPropertiesNet
16646000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
134000 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000917225
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64801373 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64801373 shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39278
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
SOLITARIO ZINC CORP.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1285791
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4251 Kipling St. Suite 390
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wheat Ridge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80033
CY2023Q1 dei City Area Code
CityAreaCode
303
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
534-1030
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
XPL
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21671000 usd
CY2023Q1 us-gaap Exploration Expense
ExplorationExpense
275000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
476000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
387000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
621000 usd
CY2022Q1 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
27000 usd
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1000 usd
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-81000 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
21000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
329000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
377000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-380000 usd
CY2023Q1 slr Earnings Loss Per Share Basic And Diluted
EarningsLossPerShareBasicAndDiluted
-0.01
CY2022Q1 slr Earnings Loss Per Share Basic And Diluted
EarningsLossPerShareBasicAndDiluted
-0.01
CY2023Q1 slr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
64801 shares
CY2022Q1 slr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
62728 shares
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
10000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
10000 usd
CY2023Q1 slr Unrealized Gain Loss On Short Term Investments
UnrealizedGainLossOnShortTermInvestments
-21000 usd
CY2022Q1 slr Unrealized Gain Loss On Short Term Investments
UnrealizedGainLossOnShortTermInvestments
51000 usd
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
13000 usd
CY2022Q1 slr Loss On Sale Of Marketable Equity Securities
LossOnSaleOfMarketableEquitySecurities
81000 usd
CY2022Q1 us-gaap Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
1000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-50000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-20000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-685000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-597000 usd
CY2023Q1 slr Purchase Sale Of Short Term Investments Net
PurchaseSaleOfShortTermInvestmentsNet
809000 usd
CY2022Q1 slr Purchase Sale Of Short Term Investments Net
PurchaseSaleOfShortTermInvestmentsNet
-1578000 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26000 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
10000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
809000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1562000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2023000 usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2042000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
124000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-117000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
316000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
462000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
440000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
345000 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Solitario faces risks related to health epidemics and other outbreaks of communicable diseases, which could significantly disrupt its operations and may materially and adversely affect its business and financial condition.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Solitario’s business still could be adversely impacted by the effects of the coronavirus (“COVID-19”) or other epidemics or pandemics. Solitario continues to evaluate the effects of COVID-19 on its operations and at times during the pandemic has taken pro-active steps to address the impacts on its operations, including reducing costs, in response to the economic uncertainty associated with potential risks from COVID-19. These prior cost reductions included implementing salary reductions and evaluating and reducing certain planned exploration programs through its joint venture partners at the Florida Canyon and Lik exploration projects. Certain of Solitario’s joint venture partners have, from time to time, modified plans with respect to the projects in which Solitario holds an interest in response to the COVID-19 pandemic. Also, Solitairo has evaluated the potential impacts on its ability to access future traditional funding sources on the same or reasonably similar terms as in past periods. Solitario will continue to monitor the effects of COVID-19 on its operations, financial condition, and liquidity. However, the extent to which COVID-19 or other epidemics or pandemics ultimately impact Solitario’s business, including its exploration and other activities and the market for its securities, will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of any new outbreak and the actions taken to contain or treat the COVID-19 pandemic or other epidemics or pandemics.</p>
CY2023Q1 slr Cash And Cash Equivalents Held In Brokerage Accounts And Foreign Banks
CashAndCashEquivalentsHeldInBrokerageAccountsAndForeignBanks
425000 usd
CY2023Q1 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
3163000 usd
CY2023Q1 slr Maturities Period Of Current Assets In United States Treasury Securities
MaturitiesPeriodOfCurrentAssetsInUnitedStatesTreasurySecurities
30 days to 11 months
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5390000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5440000 shares
CY2023Q1 us-gaap Mineral Properties Net
MineralPropertiesNet
16646000 usd
CY2022Q4 us-gaap Mineral Properties Net
MineralPropertiesNet
16646000 usd
CY2023Q1 us-gaap Exploration Expense
ExplorationExpense
275000 usd
CY2022Q1 us-gaap Exploration Expense
ExplorationExpense
226000 usd
CY2023Q1 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
1278000 usd
CY2022Q4 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
949000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
1440000 usd
CY2022Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
1440000 usd
CY2023Q1 slr Unrealized Gain Loss On Marketable Equity Securities
UnrealizedGainLossOnMarketableEquitySecurities
-162000 usd
CY2022Q4 slr Unrealized Gain Loss On Marketable Equity Securities
UnrealizedGainLossOnMarketableEquitySecurities
-491000 usd
CY2023Q1 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
1278000 usd
CY2022Q4 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
949000 usd
CY2023Q1 slr Cost Of Marketable Equity Securities Sold
CostOfMarketableEquitySecuritiesSold
0 usd
CY2022Q1 slr Cost Of Marketable Equity Securities Sold
CostOfMarketableEquitySecuritiesSold
107000 usd
CY2023Q1 slr Realized Gain On Marketable Equity Securities Sold
RealizedGainOnMarketableEquitySecuritiesSold
0 usd
CY2022Q1 slr Realized Gain On Marketable Equity Securities Sold
RealizedGainOnMarketableEquitySecuritiesSold
-81000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
0 usd
CY2022Q1 us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
26000 usd
CY2023Q1 slr Net Gain Losses On Marketable Securities
NetGainLossesOnMarketableSecurities
329000 usd
CY2022Q1 slr Net Gain Losses On Marketable Securities
NetGainLossesOnMarketableSecurities
132000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
106000 usd
CY2023Q1 slr Net Gain Losses On Marketable Securities
NetGainLossesOnMarketableSecurities
329000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
213000 usd
CY2023Q1 slr Realized Gain On Marketable Equity Securities Sold
RealizedGainOnMarketableEquitySecuritiesSold
0 usd
CY2022Q1 slr Realized Gain On Marketable Equity Securities Sold
RealizedGainOnMarketableEquitySecuritiesSold
-81000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
329000 usd
CY2022Q1 slr Net Gain Losses On Marketable Securities
NetGainLossesOnMarketableSecurities
132000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
25000 usd
CY2023Q1 us-gaap Interest Portion Of Minimum Lease Payments Sale Leaseback Transactions
InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions
0 usd
CY2023Q1 slr Present Value Of Leases Payments
PresentValueOfLeasesPayments
25000 usd
CY2023Q1 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
11000 usd
CY2022Q1 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
11000 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
118000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
134000 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
3163000 usd
CY2023Q1 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
1278000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
3951000 usd
CY2022Q4 slr Investments In Marketable Equity Securities At Fair Value
InvestmentsInMarketableEquitySecuritiesAtFairValue
949000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
550000 usd
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P29M
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21646000 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
67000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-380000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21333000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23183000 usd
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
13000 usd
CY2022Q1 slr Issuance Of Shares Atm Net Value
IssuanceOfSharesAtmNetValue
2023000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
19000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-514000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
24724000 usd

Files In Submission

Name View Source Status
slr-20230331_cal.xml Edgar Link unprocessable
0001654954-23-005861-index-headers.html Edgar Link pending
0001654954-23-005861-index.html Edgar Link pending
0001654954-23-005861.txt Edgar Link pending
0001654954-23-005861-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slr-20230331.xsd Edgar Link pending
sodi_10q.htm Edgar Link pending
sodi_ex311.htm Edgar Link pending
sodi_ex312.htm Edgar Link pending
sodi_ex321.htm Edgar Link pending
slr-20230331_lab.xml Edgar Link unprocessable
slr-20230331_def.xml Edgar Link unprocessable
slr-20230331_pre.xml Edgar Link unprocessable
sodi_10q_htm.xml Edgar Link completed